Health

Tertiary education and workplace reforms vital to address an Asian Pacific crisis in fertility rates

MANILA, Philippines, May 27, 2024 /PRNewswire/ -- Asian Pacific leaders in reproductive health are calling on tertiary education sectors and employers to introduce family friendly study programs and workplace flexibility measures to help arrest an alarming decline in birth rates. In many count...

2024-05-27 09:42 1880

Telix Submits NDA for New Prostate Cancer Imaging Agent

MELBOURNE, Australia, May 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) tothe United States (U.S.) Food and Drug Administration (FDA) for TLX007-CDx, a new and proprietary cold kit ("Kit") for th...

2024-05-27 07:21 1909

Critical need for doctors to counsel couples on potential genetic burden in offspring of older dads

MANILA, Philippines, May 26, 2024 /PRNewswire/ -- An increasing trend of older fatherhood is potentially creating a global genetic disaster with devastating health consequences for offspring. A major conference of human reproductive health in the Philippines will hear of mounting evidence that...

2024-05-26 15:59 2666

YS Biopharma Announces Name Change to LakeShore Biopharma

GAITHERSBURG, Md., May 24, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...

2024-05-24 19:30 2011

61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals

STOCKHOLM, May 24, 2024 /PRNewswire/ -- A pioneering study, presented today at the 61st ERA Congress, has demonstrated that semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality in patients with type 2 diabetes and chronic kidn...

2024-05-24 19:00 2935

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting

* The ELECTRA and ELEVATE studies were designed to overcome different resistance mechanisms and improve patient outcomes with oral-oral combination options. * Updated results from the ELECTRA study, evaluating elacestrant in combination with abemaciclib regardless of metastatic site,show a sa...

2024-05-24 17:36 2550

Compassionate closure for those who are unable to fulfil hopes and expectations of fertility treatment

MANILA, Philippines, May 24, 2024 /PRNewswire/ -- Compassionate closure is a vital aspect of the holistic care of millions of people each year who are left with lost hopes and dreams of parenthood after assisted conception. In the dynamic and rapidly expanding field of assisted reproductive te...

2024-05-24 16:00 1991

United in Our Fight Against Cancer - New Frontier Group Acquires Hong Kong Integrated Oncology Centre

HONG KONG, May 24, 2024 /PRNewswire/ -- New Frontier Group (hereinafter referred to as "New Frontier") announces today that it has completed the acquisition of Hong Kong Integrated OncologyCentre (hereinafter referred to as "HKIOC"), a leading comprehensive private oncology medical platform. Thro...

2024-05-24 13:59 2713

CStone Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website

* CS5001 is the first known ROR1 antibody-drug conjugate (ADC) to demonstrate clinical anti-tumor activity in both solid tumors and lymphomas, and among the top two globally in clinical development. * First-in-human study data show that CS5001 is well tolerated with promising anti-tumor activ...

2024-05-24 13:00 2265

Busting fear barrier about hormone replacement therapy in new era of menopause management

MANILA, Philippines, May 24, 2024 /PRNewswire/ -- Millions of women around the world continue to suffer unnecessarily from the physical and psychological effects of the menopause because of "mistaken fears" about the risks and benefits of hormone replacement therapy. A world leader in human fe...

2024-05-24 09:00 1915

Antengene To Present One Oral and Four Abstracts at ASCO 2024

* Oral Presentation:a Phase II study of ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in patients with cervical cancer * Three Poster presentations: Phase I/II studies of ATG-031 (anti-CD24 monoclonal antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), and selinexor(XPO1 Inh...

2024-05-24 08:30 2882

Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024

Phase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression, including in patients with PD-L1 CPS<5. PRINCETON, N.J. and SUZHOU, China, May 24, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharm...

2024-05-24 08:00 2317

ONCOCLÍNICAS APPROVES R$ 1.5 BILLION CAPITAL INCREASE

Operation aims to strengthen the Company's financial position and maintain growth strategy SAO PAULO, May 24, 2024 /PRNewswire/ -- Oncoclínicas&Co (B3: ONCO3), a leading oncology company headquartered inLatin America, has announced that the enterprise has approved a capital increase ofR$ 1.5 bil...

2024-05-24 06:41 1957

Providence and Ontario Institute for Cancer Research (OICR) partnering to discover and develop mRNA therapeutics

CALGARY, AB and TORONTO, May 23, 2024 /PRNewswire/ -- Providence Therapeutic Holdings Inc. ("Providence"), a messenger RNA (mRNA) and lipid nanoparticle platform company engaged in the development of vaccines and therapeutics, and the Ontario Institute for Cancer Research (OICR),Ontario's largest...

2024-05-23 21:05 1347

Guo Guangchang: Fosun Steadfastly Focuses on Innovation + Globalization

HONG KONG, May 23, 2024 /PRNewswire/ -- The 4th BEYOND International Technology Innovation Expo (BEYOND Expo 2024) commenced with a spectacular opening ceremony on 22 May at the Venetian Theatre in the Venetian Macao. At the opening ceremony, Guo Guangchang, Chairman of Fosun International, said ...

2024-05-23 18:31 3956

New report from Access to Medicine Foundation shows what pharma companies can do to ensure the few promising antimicrobials in development reach patients on the frontlines of drug resistance

AMSTERDAM, May 23, 2024 /PRNewswire/ -- The race to create replacement antibiotics and antifungals to combat superbugs is falling dangerously short, putting people across the world at risk. However, a shift in research and development (R&D), including investment in access and stewardship planning...

2024-05-23 18:00 1737

Manulife Launches a Two-Year Strategic Charity Partnership with Mind HK

Key initiatives aim to address misconceptions towards mental health and empower sustained health and well-being                            HONG KONG, May 23, 2024 /PRNewswire/ -- Manulife Hong Kong today announced a two-year strategic partnership with Mind HK, aHong Kong-based mental health char...

2024-05-23 14:06 3471

Revolutionising Cardiac Care at Pantai Hospital Kuala Lumpur

Advanced TAVI Procedure on Patient with Severe Aortic Stenosis KUALA LUMPUR, Malaysia, May 23, 2024 /PRNewswire/ -- Pantai Hospital Kuala Lumpur (PHKL), a leader in medical excellence and patient care, has achieved another significant medical milestone with the successful launch of its Transcath...

2024-05-23 11:22 12041

MediThinQ Unveils SCOPEYE 3D Micro Surgery Solution; Chris Lee of VentureBlick Assumes Chairmanship

SINGAPORE, May 23, 2024 /PRNewswire/ -- MediThinQ, the Korean startup pioneering extended reality (XR) wearable displays for surgical applications, unveils its groundbreaking SCOPEYE 3D Micro Surgery Solution. This innovative microsurgery solution leverages the latest Eyes Up Display technology t...

2024-05-23 10:00 14102

Bionoxx to Highlight Innovative Strategy for Addressing Immune-Related Diseases at 2024 BIO International Conference

Corporate presentation scheduled for Tuesday, 04 June 2024 at 4:00 PM PT SAN DIEGO and SEOUL, South Korea, May 23, 2024 /PRNewswire/ -- Bionoxx Inc., an innovative biotech company developing neutrophil-directed T cell modulation technology, announced today it will unveil its novel immunomodulator...

2024-05-23 08:00 1936
1 ... 51525354555657 ... 580

Week's Top Stories